Direct answer. Mitral regurgitation is backward leakage from the left ventricle into the left atrium when the mitral valve should be closed. Primary disease involves the valve apparatus; secondary disease results from changes in the ventricle or atrium that prevent normal closure. Acute and chronic presentations also differ. Confidence is high in these distinctions; current guidance supplies attributed care context, while materially conflicted or financially unresolved device outcomes do not determine an independent verdict. NHLBI valve anatomy and types, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
- Primary leaflet/apparatus disease differs from secondary leakage related to ventricular or atrial changes.
- Mitral valve prolapse is one possible mechanism, but it is not a synonym for all leakage.
- Sudden severe regurgitation can be an emergency; chronic disease may need surveillance before symptoms become obvious.
- Heart-failure or rhythm treatment and a valve procedure have different roles in secondary disease.
- A selected repair, replacement or catheter procedure requires anatomical and clinical assessment, not a device brochure.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| What flows backward? | Public anatomy | Blood returns from left ventricle to left atrium during contraction. High confidence. |
| Are all mechanisms alike? | 2025 classification guidance | No. Primary, ventricular secondary and atrial secondary disease differ. |
| Can medication replace every intervention? | Attributed care guidance | No. The relevant underlying disease and valve indication need separate assessment. |
| Is a smaller leak proof of survival benefit? | Evidence and funding boundary | No. Imaging, symptoms, admission and survival are distinct outcomes. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
The mitral valve sits between the left atrium and left ventricle. It opens during filling and should close during ventricular contraction. Regurgitation allows blood to return to the atrium. It is also called mitral insufficiency. Severity matters, but the mechanism and whether the leak developed abruptly or over time also affect care. NHLBI valve anatomy and types, March2022.
In primary disease, a leaflet, supporting cord or papillary-muscle component is abnormal. Degenerative prolapse, rheumatic disease, infection or an acute injury can be relevant. In secondary disease, altered chamber geometry and supporting structures prevent adequate leaflet closure even when the leaflet tissue is not the original problem. The current guideline distinguishes ventricular and atrial secondary patterns because their management is not identical. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
A murmur or scan may detect chronic leakage before a major symptom is recognized. Breathlessness, fatigue, palpitations and reduced capacity can occur, but other conditions can cause them too. Acute severe leakage, such as after a supporting-structure rupture or infection, can be poorly tolerated and needs an urgent specialist pathway. A longstanding diagnostic label does not make a new acute deterioration safe. NHLBI valve disease symptoms, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
How it works
Leakage adds flow and pressure to the left atrium and can affect the pulmonary circulation and cardiac chambers. In chronic disease, chamber enlargement and functional changes may develop gradually. A seemingly preserved ejection fraction does not describe every consequence of regurgitation or automatically establish that the valve needs no further review. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Ventricular secondary leakage can accompany an enlarged or impaired left ventricle, including a coronary-related pattern. Atrial secondary leakage involves atrial/annular enlargement and is often considered with atrial fibrillation or preserved-ejection-fraction heart failure. These patterns can overlap in advanced disease. A mechanism label needs imaging and clinical interpretation, rather than selection from symptoms alone. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Echo usually provides the initial evaluation of anatomy, integrated leak severity, ventricular and atrial size/function and associated valve or right-heart findings. Transoesophageal echo can define anatomy for repair planning; MRI, selected CT or other testing can answer unresolved questions. One colour-flow picture cannot establish every aspect of severity, and a wearable rhythm result cannot classify the valve mechanism. NHLBI valve disease diagnosis, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
The evidence-based treatments
For chronic primary regurgitation, care may involve surveillance or a valve intervention assessment according to established severity, symptoms and cardiac effects. The 2025 guideline favours surgical repair in appropriate operable anatomy when a durable result is expected; replacement or selected catheter treatment may be considered when the circumstances differ. This is attributed professional guidance, not an independent numerical superiority claim. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
In ventricular secondary disease, the current guidance prioritizes appropriate heart-failure treatment and selected resynchronization when indicated before a mitral intervention decision. Persistent important leakage and symptoms then prompt a multidisciplinary assessment of anatomy, clinical suitability and goals. Correcting the valve does not remove the underlying muscle or coronary disorder. Treatment and monitoring remain individualized; no personal drug sequence or titration is provided. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Atrial secondary disease requires its own review of rhythm, heart failure, congestion and valve anatomy. It should not receive a procedure simply because it shares the word secondary with a ventricular case. The August 2026 official correction to the guideline was checked; this guide avoids the erroneous symptom-class wording in the older PDF and offers no numerical self-selection criteria. Official August6,2026 correction to2025 valve guideline; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Procedural goals and evidence must be kept distinct. Reducing a leak on echo, improving symptoms, reducing hospital admissions and extending life are different claims. Trial selection, background treatment and follow-up can change results, while device-related finances can change independence. A professional summary does not make a sponsored underlying study independent; this article gives no universal catheter-device ranking or financially uncleared outcome estimate. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Supplement and lifestyle evidence
Discuss safe activity and any need for a heart-failure or rehabilitation plan. Smoking cessation, appropriate nutrition and management of other cardiovascular risks support overall care but do not prove correction of a leaflet or chamber-geometry problem. A potassium, fluid or salt plan should follow the actual illness and medicines rather than a generic heart-support diet. NHLBI valve care background, March2022.
No supplement is established here as a treatment for mitral regurgitation. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.
What works and what does not
Useful care specifies the mechanism, current severity, ventricular/atrial and pulmonary findings, symptoms and the reason for surveillance or intervention. It identifies the intended outcome and how it will be assessed. After a repair or catheter procedure, underlying heart-failure or rhythm management may remain necessary; improvement in one echo measurement does not settle every future risk. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.
Risks and side effects
Severe or rapidly worsening breathlessness, collapse or new concerning chest pain needs emergency help. A new acute change should not be assumed to be the familiar chronic leak or anxiety. Significant new palpitations, fainting or declining capacity deserves prompt clinical review according to severity. NHS current national heart valve disease education.
Surgical or catheter treatment can cause bleeding, stroke, infection, kidney/cardiac injury, residual leakage or later reintervention. A catheter repair can also change the effective valve opening, so post-procedure obstruction and residual flow require assessment. Anticoagulants, diuretics and other cardiac medicines have their own bleeding, pressure, kidney or electrolyte risks. NHLBI valve care background, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Important interactions
Review anticoagulants, rate/rhythm medicines, heart-failure treatment, pain products and supplements together. Kidney function, pressure and electrolyte changes can affect safety. Before a procedure, the team should give instructions for the exact medication list; do not copy another patient’s blood-thinner stopping plan. Pregnancy planning needs a specific prescription and valve assessment. NHLBI valve disease and pregnancy, March2022; NHLBI valve care background, March2022.
Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.
Who needs assessment
Ask whether the mechanism is primary, ventricular secondary, atrial secondary or mixed; whether the leak is acute or chronic; and how the left and right heart have responded. An intervention discussion should explain whether anatomy is suitable and what other disease is being treated. Imaging and symptom findings that disagree may need further investigation rather than a reassuring conclusion from one result. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Pregnancy planning, a previous valve intervention, kidney disease and anticoagulant use deserve specific review. The current status of the valve matters more than an old diagnostic label. Children with congenital disease need an age-appropriate specialist pathway rather than an adult intervention rule. NHLBI valve disease and pregnancy, March2022.
Clinician-led use and follow-up
Ask which repeat imaging and clinical findings will track leakage, cardiac response and any underlying disease, and when new symptoms should trigger earlier contact. After intervention, clarify repair/prosthesis surveillance, antithrombotic treatment and procedural precautions. This guide gives no personal dose, scan threshold or device-selection checklist; a written clinical plan should explain the actual indications and uncertainties. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.
Animal and in-vitro evidence
Laboratory work on valve calcification, connective tissue or blood-flow mechanics can help investigate a mechanism. It cannot determine a safe human supplement dose, establish that a calcified valve will reopen, or select an implant for an individual. An animal or cell finding does not replace a clinical assessment of anatomy, severity and complications. No animal or in-vitro result contributes to this guide’s independent clinical verdict.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 17 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Financial interests include echocardiography and advanced imaging, valve implants, surgical and catheter services, medicines and marketed supplements. Valve-device manufacturers and professional societies can have relevant financial relationships even when the document itself reports no direct industry-development funding. Those routes and unresolved author/trial chains are shown below; no manufacturer or materially conflicted outcome claim establishes this guide’s independent verdict.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI valve anatomy and types, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public anatomy and distinctions between stenosis, regurgitation and prolapse. |
| NHLBI valve disease causes, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public inherited and acquired contributor education. |
| NHLBI valve disease symptoms, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Public symptom education; symptoms do not establish severity. |
| NHLBI valve disease diagnosis, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Clinical investigation background; no self-diagnostic thresholds. |
| NHLBI valve care background, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced. |
| NHS current national heart valve disease education | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: January 2025 national condition and emergency education; broad prolapse wording not reproduced. |
| Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF | The original guideline states document development was financed entirely by ESC and EACTS without healthcare-industry involvement. ESC institutional revenues nevertheless include life-science and medtech partnerships; EACTS discloses industry/charity grants and an Edwards Lifesciences Foundation partnership. That separate route does not prove Edwards funded this guideline. The official 2025 author declaration report returned 403 and was not read. Article allocation, individual author independence and original device/drug trial chains remain unresolved. | France: ESC, Sophia Antipolis. United Kingdom: EACTS, Windsor, registered England and Wales; OUP publisher UK. International writing panel. The unchanged original EJCTS PDF mirror is hosted by MATCVS, Malaysia; it does not change the document author or funding origin. Edwards corporate headquarters Irvine, California, US; specific supplied-device manufacturing origin unresolved. | Tier 2 documented society industry routes, with unresolved author chain; independent efficacy excluded. | C provisional. Original 109-page guideline and August 2026 correction checked. Detailed methodology, specialist review and explicit evidence grades aid attributed clinical use; society commercial routes, inaccessible author declarations and uncleared original-trial finances prevent a clean independent outcome verdict. Role: Current 2025 specialist care context with August2026 correction checked; C provisional, not independent efficacy. |
| Official August6,2026 correction to2025 valve guideline | The original guideline states document development was financed entirely by ESC and EACTS without healthcare-industry involvement. ESC institutional revenues nevertheless include life-science and medtech partnerships; EACTS discloses industry/charity grants and an Edwards Lifesciences Foundation partnership. That separate route does not prove Edwards funded this guideline. The official 2025 author declaration report returned 403 and was not read. Article allocation, individual author independence and original device/drug trial chains remain unresolved. | France: ESC, Sophia Antipolis. United Kingdom: EACTS, Windsor, registered England and Wales; OUP publisher UK. International writing panel. The unchanged original EJCTS PDF mirror is hosted by MATCVS, Malaysia; it does not change the document author or funding origin. Edwards corporate headquarters Irvine, California, US; specific supplied-device manufacturing origin unresolved. | Tier 2 documented society industry routes, with unresolved author chain; independent efficacy excluded. | C provisional. Original 109-page guideline and August 2026 correction checked. Detailed methodology, specialist review and explicit evidence grades aid attributed clinical use; society commercial routes, inaccessible author declarations and uncleared original-trial finances prevent a clean independent outcome verdict. Role: Actual August2026 correction to secondary MR wording; no clinical outcome evidence. |
| NHLBI valve disease and pregnancy, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Pregnancy and prescription-safety education. |
| NHLBI valve disease definitions, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| ESC funding and revenue model | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| ESC conflict management policy | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| EACTS current industry/charity grant and Edwards Foundation relationship | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS industry sponsorship route | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS registered jurisdiction and Windsor contact | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| Edwards corporate/foundation funding and technology-donation routes | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
| Edwards global headquarters and manufacturing-location disclosure | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
Frequently asked questions
Is prolapse the same as regurgitation? No. Prolapse describes leaflet movement and can occur without important leakage. Regurgitation describes backward flow and has other causes. NHLBI valve anatomy and types, March2022.
Does a clip procedure cure heart failure? A selected valve procedure targets the leak. Underlying ventricular disease, rhythm problems or other causes can still require treatment and follow-up. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Can I wait until I feel very breathless? Important chronic disease may need imaging review or intervention discussion before severe symptoms. Ask how the team is monitoring ventricular and other consequences. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Can medicine prevent every operation? No. Medication has specific associated indications; the need for a valve intervention depends on mechanism, severity and the broader assessment. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Sources and funding notes
- NHLBI valve anatomy and types, March2022 — Dated public anatomy and distinctions between stenosis, regurgitation and prolapse.
- NHLBI valve disease causes, March2022 — Dated public inherited and acquired contributor education.
- NHLBI valve disease symptoms, March2022 — Public symptom education; symptoms do not establish severity.
- NHLBI valve disease diagnosis, March2022 — Clinical investigation background; no self-diagnostic thresholds.
- NHLBI valve care background, March2022 — Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced.
- NHS current national heart valve disease education — January 2025 national condition and emergency education; broad prolapse wording not reproduced.
- Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF — Current 2025 specialist care context with August2026 correction checked; C provisional, not independent efficacy.
- Official August6,2026 correction to2025 valve guideline — Actual August2026 correction to secondary MR wording; no clinical outcome evidence.
- NHLBI valve disease and pregnancy, March2022 — Pregnancy and prescription-safety education.
- NHLBI valve disease definitions, March2022 — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- ESC funding and revenue model — Financial provenance only.
- ESC conflict management policy — Financial provenance only.
- EACTS current industry/charity grant and Edwards Foundation relationship — Financial provenance only.
- EACTS industry sponsorship route — Financial provenance only.
- EACTS registered jurisdiction and Windsor contact — Financial provenance only.
- Edwards corporate/foundation funding and technology-donation routes — Financial provenance only.
- Edwards global headquarters and manufacturing-location disclosure — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. The original 109-page 2025 ESC/EACTS valve guideline was read from MATCVS’s unchanged EJCTS/OUP PDF mirror, with its title, authors and DOI verified. The official August 6, 2026 correction was opened separately. The official author-declaration PDF returned 403 and was not read. Actual ESC, EACTS and Edwards financial-route disclosures were checked; separate institutional industry support does not establish direct industry financing of this document. Individual author and original-trial financial chains remain unresolved; clinical recommendations are C-provisional context. Clinical sources concentrate on US and English public education plus European professional guidance. This limits jurisdictional breadth: referral, implant availability and treatment systems vary, and no global access claim is inferred. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.